Back

Treatment of Post-COVID-19 POTS by inhibiting FcRn: a phase 2 randomized, placebo controlled, double-blind, proof of concept study with efgartigimod

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Long-term impact of COVID-19: direct and indirect consequences Autoimmune/Chronic Inflammatory Disorders and Heart Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Joost van Middendorp

Gent (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Substantial morbidity and mortality due to cardiovascular diseases in hospitalized vaccinated and un-vaccinated patients with COVID-19 from 16 countries: the WHF COVID-19 Long-term study
Doctor K. Singh (Gurgaon, IN)
Abstract Slides Video
Presentation thumbnail
Vaccination status and long COVID symptoms among patients hospitalized with COVID-19: the WHF COVID-19 Long-term Study
Professor D. Prabhakaran (Gurgaon, IN)
Abstract Slides Video
Presentation thumbnail
Effect of COVID-19 pandemic on the management of hypertension and the prevalence of lifestyle disease
Doctor T. Isogaki (Hamamatsu, JP)
Abstract Slides Video
Presentation thumbnail
Effects of deferment of clinic visit on cardiovascular outcomes during COVID-19 outbreak: a prospective cohort study
Assistant Professor G. Tan (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
The effect of 2 years COVID-19 pandemic on myocardial infarction and stroke admissions: nationwide registry study, sex differences and mortality
Assistant Professor P. Sedova (Brno, CZ)
Abstract Slides Video

Access the full session

Session thumbnail
Long-term impact of COVID-19: direct and indirect consequences
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources